Ani Pharmaceuticals Inc
ANIP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001023024
In the last 90 days, Ani Pharmaceuticals Inc insiders filed 0 open-market purchases and 10 sales; 307 institutions reported holding it in 13F filings for Q2 2026, worth $1.90B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Ani Pharmaceuticals Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 10 filings
- 5 insiders, $1.94M in total
- Insiders trading
- 5
- Net value
- −$1.94M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Ani Pharmaceuticals Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Lalwani Nikhil | PRESIDENT & CEO | 339,089 | Sep 16, 2026 | 7 |
| Thoma Jeanne | Director | 26,762 | Sep 14, 2026 | 2 |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | 73,924 | Sep 14, 2026 | 15 |
| Carey Stephen P. | SVP & CFO | 171,843 | Sep 1, 2026 | 10 |
| Gosebruch Henry O | Director | 6,662 | Aug 27, 2026 | 1 |
| Gutwerg Ori | SVP, GENERICS | 75,534 | Aug 11, 2026 | 7 |
| Haughey Thomas | Director | 38,878 | Jun 10, 2026 | 1 |
| Tannenbaum Renee P | Director | 29,514 | Jun 10, 2026 | 2 |
| Pera Antonio R | Director | 27,017 | Jun 10, 2026 | 1 |
| Leonard Matthew J | Director | 11,221 | Jun 10, 2026 | 1 |
| Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | 38,271 | May 13, 2026 | 5 |
| Walsh Patrick D | Director | 38,432 | May 13, 2026 | 3 |
| Mutz Christopher | HEAD OF RARE DISEASE | 91,309 | Mar 13, 2026 | 7 |
| Davis Krista | SVP, CHIEF HR OFFICER | 51,946 | Mar 10, 2026 | 6 |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | 101,056 | Mar 2, 2026 | 2 |
| Gassert Chad | SVP - CORP. DEV. & STRATEGY | 74,916 | Mar 2, 2026 | 4 |
| Marken James G. | SVP OPS & PROD DEV | 117,829 | Jun 11, 2024 | 0 |
| Meridian Venture Partners II LP | 10% Owner | 1,819,259 | Aug 16, 2023 | 0 |
| Brown Robert E. JR | 10% Owner | 1,819,259 | Aug 16, 2023 | 0 |
| Meridian Venture Partners II, Co. | 10% Owner | 1,819,259 | Aug 16, 2023 | 0 |
| Meridian Venture Partners II GP, L.P. | 10% Owner | 1,819,259 | Aug 16, 2023 | 0 |
| Nash David | Director | 38,561 | May 24, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 9, 2021 (view filing) | Dec 7 | 2 days | Pera Antonio RDirector | PPurchase | +3.00K | $42.26 | +$126.8K | +18.0%19.7K after | |
| Dec 7, 2021 (view filing) | Dec 6 | 1 day | Haughey ThomasDirector | PPurchase | +2.50K | $39.38 | +$98.5K | +9.0%30.2K after |